Express Pharma

Mylan to supply ARVs to South African National Department of Health

0 109

Mylan announced that its subsidiary in India, Mylan Laboratories, a leading manufacturer of antiretroviral (ARV) drugs, has been selected, through its South African-based subsidiary Mylan (Proprietary) Limited (Mylan Limited), as one of the leading suppliers of ARV drugs to the South African National Department of Health for the tender period January 1, 2013 to December 31, 2014.

Mylan Limited secured a R1.12 billion share, which represents 19.1 per cent of the R5.9 billion tender value. As a part of this award, Mylan will supply the South African Government with 31 per cent of the 30 million units of triple therapy fixed dose combination (FDC) called for in the tender.

Mylan CEO Heather Bresch commented, “Mylan’s mission is to provide the world’s 7 billion people access to high quality medicines, including affordable ARVs. Only through access to these vital medicines can we stem the tide of HIV/AIDS in South Africa and around the world. This award reinforces Mylan’s commitment to provide high quality advanced drugs to help people suffering from HIV/AIDS in South Africa, and we are proud to have been selected as a partner to the South African Department of Health.”

“We believe Mylan’s selection as a leading supplier to the South African Government’s ARV tender reflects our vertical integration, quality manufacturing, global scale and proven-track record of being a reliable partner in supplying affordable ARV medicines across the world. We are pleased to bring this global scale, quality and reliability to the South African market and continue our legacy in fighting HIV/AIDS,” said Paul Miller, Managing Director and Vice President of Mylan’s South African business.

Mylan supplies ARV drugs to more than 120 countries around the world and approximately one-third of HIV/AIDS patients receiving treatment in developing countries depend on a Mylan ARV product. Mylan will be entering the South African market with a comprehensive portfolio of ARV drugs, consisting of first- and second-line adult and pediatric therapies, including several dual and triple FDCs.

EP News BureauMumbai

- Advertisement -

Leave A Reply

Your email address will not be published.